Bamco Inc Esperion Therapeutics, Inc. Transaction History

Bamco Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$19.4 - $28.71 $7.25 Million - $10.7 Million	-373,500 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$24.2 - $35.76 $968,000 - $1.43 Million	40,000 Added 11.99%	373,500 $9.71 Million
Q3 2020 Nov 13, 2020	BUY	$31.18 - $52.71 $1.4 Million - $2.37 Million	45,000 Added 15.6%	333,500 $12.4 Million
Q2 2020 Aug 14, 2020	BUY	$30.04 - $51.31 $3 Million - $5.13 Million	100,000 Added 53.05%	288,500 $14.8 Million
Q2 2019 Aug 15, 2019	BUY	$40.1 - $52.33 $200,500 - $261,650	5,000 Added 2.72%	188,500 $8.77 Million

Q1 2019 May 15, 2019	BUY	$40.11 - $53.57 $3.35 Million - $4.47 Million	83,500 Added 83.5%	183,500 $7.37 Million
Q3 2018 Nov 14, 2018	BUY	$40.74 - $51.41 $3.43 Million - $4.32 Million	84,100 Added 528.93%	100,000 $4.44 Million
Q2 2018 Aug 14, 2018	SELL	$36.2 - $76.4 $325,800 - $687,600	-9,000 Reduced 36.14%	15,900 $623,000
Q1 2018 May 09, 2018	BUY	$65.94 - $80.76 $791,280 - $969,120	12,000 Added 93.02%	24,900 $1.8 Million
Q4 2017 Feb 14, 2018	BUY	$43.47 - $67.43 $560,763 - $869,847	12,900	12,900 $849,000

174

125M

2.08M

1.01M

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Bamco Inc , based on Form 13F filings with the SEC.

Stay updated on Bamco Inc with notifications on news.